Singapore markets closed
  • Straits Times Index

    2,949.04
    -24.50 (-0.82%)
     
  • Nikkei

    28,966.01
    -1,202.26 (-3.99%)
     
  • Hang Seng

    28,980.21
    -1,093.96 (-3.64%)
     
  • FTSE 100

    6,495.63
    -156.33 (-2.35%)
     
  • BTC-USD

    47,566.74
    -3,529.13 (-6.91%)
     
  • CMC Crypto 200

    953.10
    +19.97 (+2.14%)
     
  • S&P 500

    3,838.19
    +8.85 (+0.23%)
     
  • Dow

    31,207.50
    -194.51 (-0.62%)
     
  • Nasdaq

    13,253.78
    +134.35 (+1.02%)
     
  • Gold

    1,726.70
    -48.70 (-2.74%)
     
  • Crude Oil

    62.33
    -1.20 (-1.89%)
     
  • 10-Yr Bond

    1.4940
    -0.0240 (-1.58%)
     
  • FTSE Bursa Malaysia

    1,577.75
    -3.79 (-0.24%)
     
  • Jakarta Composite Index

    6,241.80
    -47.85 (-0.76%)
     
  • PSE Index

    6,794.86
    +38.91 (+0.58%)
     

Quantum Leap and SignalPath Partner to Integrate Clinical Trial Software Infrastructure Across I-SPY Platform Trials

·3-min read

Quantum Leap Healthcare Cooperative (Quantum Leap) and SignalPath announced a partnership today that will further empower the I-SPY platform trials with robust, streamlined technology infrastructure to drive the ease and efficiency of trial execution. SignalPath will integrate existing workflow tools being used to power the I-SPY trials into SignalPath’s research operations and financial platform. Based on the public health emergency surrounding the COVID-19 pandemic, this advanced technology infrastructure will initially be deployed for I-SPY COVID-19 with subsequent expansion to I-SPY2.

"As we continue to grow our platform trials with a focus on I-SPY COVID-19, and the growing complexity of processing drug candidates through our platform trials, we need sophisticated infrastructure to ensure we can maintain our efficiency and agility. SignalPath provides the missing link for a comprehensive, tech-enabled trial technology platform to unlock the full potential of adaptive trial designs. This further empowers us to address urgent health needs that can only be solved through exceptional, technology-enabled clinical research," observed James Palazzolo, CEO of Quantum Health.

The I-SPY platform has had incredible success in working with leading academic medical centers around the United States. SignalPath is helping to expand that footprint across the world-class community health systems on the SignalPath platform. The goal is to continue to engage community health systems with robust research programs in cutting edge research to support their patients.

"We founded SignalPath to re-imagine clinical trial execution through technology," stated Brad Hirsch, MD, CEO and Co-Founder, SignalPath. "The Quantum Leap team has already accomplished an amazing amount in the fight against breast cancer and is now applying their full force to drive insights into COVID-19. It is an incredible opportunity for us to collaboratively support trial execution through our powerful technology infrastructure to meaningfully reduce the complexity for both the Quantum Leap team and the sites involved in the I-SPY trials. Everyone’s goal is the same - to bring life-saving medicines to patients that need them most."

About SignalPath

SignalPath is the premier clinical trial technology partner for research sites and sponsors, focused on improving the ease and efficiency of trial execution and management. Supporting over 5,000 trials across more than 300 sites and thousands of active users, SignalPath is the industry standard that addresses key pain points in the conduct of trials. To learn more about SignalPath's site and trial solutions, please visit www.signalpath.com.

About Quantum Leap Healthcare Collaborative

Quantum Leap Healthcare Collaborative is a 501c(3) charitable organization established in 2005 as a collaboration between medical researchers at University of California, San Francisco and Silicon Valley entrepreneurs. Our mission is to integrate care and research, and to foster high-impact trials with embedded clinical processes and systems technology and improved data management, greater access to clinical trial matching, and greater benefit to patients, providers, and researchers. Our goal is to improve and save lives. Quantum Leap provides operational, financial, and regulatory oversight to I-SPY. For more information, visit https://www.quantumleaphealth.org/.

About the I-SPY TRIALs

The I-SPY TRIAL (Investigation of Serial studies to Predict Your Therapeutic Response with Imaging And moLecular analysis) was designed to rapidly screen promising experimental treatments and identify those most effective in specific patient subgroups based on molecular characteristics (biomarker signatures). The trial is a unique collaborative effort by a consortium that includes the Food and Drug Administration (FDA), industry, patient advocates, philanthropic sponsors, and clinicians from 16 major U.S. cancer research centers. Under the terms of the collaboration agreement, Quantum Leap Healthcare Collaborative is the trial sponsor and manages all study operations. For more information, visit www.ispytrials.org.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005791/en/

Contacts

SignalPath LLC
Phil Perez
media@signalpath.com